Why shareholders are suing Novo Nordisk over next-generation weight-loss drug

CNBC•Wed, Jul 29, 2026, 02:59 PM•2 min read

Investors claim Novo Nordisk misled the market about CagriSema's tolerability, after disappointing clinical trial results wiped billions off its market cap.

Source: [CNBC](https://www.cnbc.com/2026/07/29/novo-nordisk-lawsuit-cagrisema-weight-loss-drug.html)

📰 Read Full Story

This is an aggregated headline summary. For the complete report, visit the original publisher.

Continue Reading at CNBC ↗

#finance #novo #nordisk #market #shareholders #suing #next #generation #weight

More Headlines

FinanceCNBC• 5m ago

Shell posts best quarterly profit in four years as Iran war boosts oil and gas prices

The bumper result comes as energy majors receive a profit boost from soaring fossil fuel prices amid the Iran war.

FinanceMarketWatch• 6m ago

Samsung delivers record-setting profits, but the shares still can’t catch a break from investors.

Although supply constraints are still severe and demand for its memory chips relentless, there is still skepticism among investors about the longevity of the AI capex boom and the threat of cheap chips from China.

FinanceSeeking Alpha• 7m ago

Rates Spark: The Fed Holds And The Long End Gets Nervous

Developing story — details emerging. Check the source link for the latest updates.

FinanceSeeking Alpha• 8m ago

AIB Group plc 2026 Q2 - Results - Earnings Call Presentation

Developing story — details emerging. Check the source link for the latest updates.

FinanceSeeking Alpha• 9m ago

JCDecaux SE 2026 Q2 - Results - Earnings Call Presentation

Developing story — details emerging. Check the source link for the latest updates.

FinanceSeeking Alpha• 9m ago

Rolls-Royce Holdings plc NON CUM RED PREF SHS GBP0.001 C 2026 Q2 - Results - Earnings Call Presentation

Developing story — details emerging. Check the source link for the latest updates.